Table 3.

Proposed medical therapies for treatment of patients with metastatic urothelial cancer in Japan (2018)

	First-line therapy	Second-line therapy
Cisplatin-eligible
Standard	GC (gemcitabine and cisplatin)	Pembrolizumab
Option	MVAC (methotrexate, vinblastine, adriamycin, cisplatin)	Taxane-including regimen such as PCG (paclitaxel, cisplatin, gemcitabine)
Cisplatin-ineligible
Standard	GCa (gemcitabine and carboplatin)	Pembrolizumab
Option		Taxane-including regimen such as GP (gemcitabine and paclitaxel)